BBO-11818 — Investigational Agent
KRAS Inhibitor · Phase 1 · BridgeBio Oncology Therapeutics
Mechanism of Action
Orally administered pan-KRAS inhibitor targeting multiple KRAS mutant alleles including G12V and G12A, blocking active GTP-bound KRAS signaling. Intended to overcome the allele-specific limitations of G12C-only agents.
Investigational Indications
- KRAS-mutant non-small cell lung cancer
- KRAS-mutant advanced solid tumors